Shannon M. Bates
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Shannon M. Bates has a total of 44 co-authors. Here are the top co-authors by number of shared publications:
- Alejandro Lazo-Langner
Schulich School of Medicine and Dentistry, Western University, London, ON, Canada
1 shared publication Anne-Marie Prabulos
Department of Obstetrics and Gynecology, University of Connecticut School of Medicine, Farmington, CT
1 shared publication- Anthony R. Sandre
Department of Medicine, McMaster University, Hamilton, Ontario, Canada
1 shared publication - Arnav Agarwal
University of Alberta
1 shared publication Brittany Humphries
Department of Health Research Methods, Evidence, and Impact, McMaster University, Hamilton, Canada
1 shared publicationCarlos Canelo-Aybar
Iberoamerican Cochrane Center, Biomedical Research Institute Sant Pau (IIB Sant Pau), Barcelona, Spain; Department of Pediatrics, Obstetrics, Gynaecology and Preventive Medicine, Universidad Autónoma de Barcelona, Barcelona, Spain; CIBER de Epidemiología y Salud Pública (CIBERESP), Barcelona, Spain
1 shared publication
Latest Publications
- 28 October 2026
- Published by American Society of Hematology in Blood Advances
- Vol. 10 (21) , 7197-7208
Reframing hematologic and thrombovascular care for transgender and gender-diverse individuals: a scoping review
Transgender and gender-diverse (TGD) individuals experience well-documented inequities in health care access and quality. Within hematologic and thrombovascular (thrombosis and vascular medicine) care, existing literature has largely emphasized physiologic risk, particularly thromboembolic risk associated with gender-affirming hormone therapy, whereas less attention has been paid to how care is delivered, experienced, and operationalized across clinical settings. The objective of this review was to map and synthesize the literature describing the delivery of hematologic and thrombovascular care for TGD individuals, with a focus on care gaps, facilitators, provider preparedness, and patient experience. We conducted a scoping literature review following the Preferred Reporting Items for Systematic Reviews and Meta-Analyses Extension for Scoping Reviews guidelines. MEDLINE, Embase, EmCare, and PsycINFO were searched from inception to 1 July 2025. Eligible sources included qualitative, quantitative, and mixed-methods studies addressing hematologic or thrombovascular care in TGD populations. Findings were synthesized descriptively and thematically. A total of 31 articles met the inclusion criteria. The following 4 dominant themes emerged: (1) narrow biomedical framing of thrombovascular risk; (2) variability and uncertainty in clinical decision-making; (3) patient-reported barriers related to stigma, misgendering, and fragmented care; and (4) limited provider training and system-level preparedness. Evidence addressing longitudinal management, shared decision-making, and interdisciplinary care models was sparse. The existing literature on TGD hematologic and thrombovascular care is limited in scope and heavily weighted toward risk reporting/management rather than care delivery. Substantial gaps remain in evidence informing best practices, provider education, and system design. These findings underscore the need for inclusive clinical guidance, education, and consensus-building initiatives.
- 28 October 2026
- Published by American Society of Hematology in Blood Advances
- Vol. 10 (21) , 7197-7208
Reframing hematologic and thrombovascular care for transgender and gender-diverse individuals: a scoping review
Transgender and gender-diverse (TGD) individuals experience well-documented inequities in health care access and quality. Within hematologic and thrombovascular (thrombosis and vascular medicine) care, existing literature has largely emphasized physiologic risk, particularly thromboembolic risk associated with gender-affirming hormone therapy, whereas less attention has been paid to how care is delivered, experienced, and operationalized across clinical settings. The objective of this review was to map and synthesize the literature describing the delivery of hematologic and thrombovascular care for TGD individuals, with a focus on care gaps, facilitators, provider preparedness, and patient experience. We conducted a scoping literature review following the Preferred Reporting Items for Systematic Reviews and Meta-Analyses Extension for Scoping Reviews guidelines. MEDLINE, Embase, EmCare, and PsycINFO were searched from inception to 1 July 2025. Eligible sources included qualitative, quantitative, and mixed-methods studies addressing hematologic or thrombovascular care in TGD populations. Findings were synthesized descriptively and thematically. A total of 31 articles met the inclusion criteria. The following 4 dominant themes emerged: (1) narrow biomedical framing of thrombovascular risk; (2) variability and uncertainty in clinical decision-making; (3) patient-reported barriers related to stigma, misgendering, and fragmented care; and (4) limited provider training and system-level preparedness. Evidence addressing longitudinal management, shared decision-making, and interdisciplinary care models was sparse. The existing literature on TGD hematologic and thrombovascular care is limited in scope and heavily weighted toward risk reporting/management rather than care delivery. Substantial gaps remain in evidence informing best practices, provider education, and system design. These findings underscore the need for inclusive clinical guidance, education, and consensus-building initiatives.
- 20 August 2025
- Published by Elsevier in Journal of Thrombosis and Haemostasis
- Vol. 23 (9) , 2713-2715
Stratifying and managing the risk of antithrombin deficiency in pregnancy
- 20 August 2025
- Published by Elsevier in Journal of Thrombosis and Haemostasis
- Vol. 23 (9) , 2713-2715
Stratifying and managing the risk of antithrombin deficiency in pregnancy
- Open Access
Diagnosis of deep vein thrombosis with D-dimer adjusted to clinical probability: prospective diagnostic management study
Objective To evaluate the safety and efficiency of a diagnostic algorithm for deep vein thrombosis (DVT) that uses clinical pretest probability based D-dimer thresholds to exclude DVT. Design Prospective diagnostic management study. Setting University based emergency departments or outpatient clinics in Canada. Participants Patients with symptoms or signs of DVT. Intervention DVT was considered excluded without further testing by Wells low clinical pretest probability and D-dimer 1500 ng/mL. If DVT was not diagnosed, patients did not receive anticoagulant treatment. Main outcome measure Symptomatic venous thromboembolism at three months. Results 1508 patients were enrolled and analysed, of whom 173 (11.5%) had DVT on scheduled diagnostic testing. Of the 1275 patients with no proximal DVT on scheduled testing who did not receive anticoagulant treatment, eight (0.6%, 95% confidence interval 0.3% to 1.2%) were found to have venous thromboembolism during follow-up. Compared with a traditional DVT testing strategy, this diagnostic approach reduced the need for ultrasonography from a mean of 1.36 scans/patient to 0.72 scans/patient (difference −0.64, 95% confidence interval −0.68 to −0.60), corresponding to a relative reduction of 47%. Conclusions The diagnostic strategy using a combination of clinical pretest probability and D-dimer identified a group of patients at low risk for DVT during follow-up while substantially reducing the need for ultrasound imaging. Registration ClinicalTrials.gov NCT02038530.
Open AccessDiagnosis of deep vein thrombosis with D-dimer adjusted to clinical probability: prospective diagnostic management study
Objective To evaluate the safety and efficiency of a diagnostic algorithm for deep vein thrombosis (DVT) that uses clinical pretest probability based D-dimer thresholds to exclude DVT. Design Prospective diagnostic management study. Setting University based emergency departments or outpatient clinics in Canada. Participants Patients with symptoms or signs of DVT. Intervention DVT was considered excluded without further testing by Wells low clinical pretest probability and D-dimer 1500 ng/mL. If DVT was not diagnosed, patients did not receive anticoagulant treatment. Main outcome measure Symptomatic venous thromboembolism at three months. Results 1508 patients were enrolled and analysed, of whom 173 (11.5%) had DVT on scheduled diagnostic testing. Of the 1275 patients with no proximal DVT on scheduled testing who did not receive anticoagulant treatment, eight (0.6%, 95% confidence interval 0.3% to 1.2%) were found to have venous thromboembolism during follow-up. Compared with a traditional DVT testing strategy, this diagnostic approach reduced the need for ultrasonography from a mean of 1.36 scans/patient to 0.72 scans/patient (difference −0.64, 95% confidence interval −0.68 to −0.60), corresponding to a relative reduction of 47%. Conclusions The diagnostic strategy using a combination of clinical pretest probability and D-dimer identified a group of patients at low risk for DVT during follow-up while substantially reducing the need for ultrasound imaging. Registration ClinicalTrials.gov NCT02038530.
- 1 January 2022
- Published by Elsevier in Journal of Clinical Epidemiology
- Vol. 141, 106-120
More work needed on decision analysis for shared decision-making: A scoping review
- 1 January 2022
- Published by Elsevier in Journal of Clinical Epidemiology
- Vol. 141, 106-120
More work needed on decision analysis for shared decision-making: A scoping review
- Open Access
- 1 May 2021
- Published by Elsevier in Thrombosis Research
- Vol. 201, 147-150
COVID-19 in thrombosis research: An editorial perspective
- 1 May 2021
- Published by Elsevier in Thrombosis Research
- Vol. 201, 147-150
Open AccessCOVID-19 in thrombosis research: An editorial perspective
- 1 October 2020
- Published by Elsevier in Thrombosis Research
- Vol. 194, 54-56
The challenges and lessons learned in conducting clinical trials in pregnant women with antiphospholipid syndrome
- 1 October 2020
- Published by Elsevier in Thrombosis Research
- Vol. 194, 54-56
The challenges and lessons learned in conducting clinical trials in pregnant women with antiphospholipid syndrome
- 19 April 2016
- Published by Taylor & Francis
- p. 219-242
Anticoagulation in Pregnancy
Anticoagulants are indicated during pregnancy for the prevention and treatment of venous thromboembolism (VTE), in patients with mechanical heart valves, as well as for the prevention of pregnancy loss in women with antiphospholipid antibodies (APLA). Anticoagulant therapy is also increasingly being employed for prevention of pregnancy complications in women with hereditary thrombophilia. Anticoagulant use during pregnancy is challenging because of the potential for fetal, as well as maternal, complications and because there is a paucity of high-quality clinical trials in this patient population upon which to make management decisions. This chapter will review the use of anticoagulants during pregnancy and in breast-feeding women and provide recommendations for the treatment and prevention of VTE, anticoagulant management in women with prosthetic mechanical valves, and prevention of pregnancy complications in women with thrombophilias.
- 19 April 2016
- Published by Taylor & Francis
- p. 219-242
Anticoagulation in Pregnancy
Anticoagulants are indicated during pregnancy for the prevention and treatment of venous thromboembolism (VTE), in patients with mechanical heart valves, as well as for the prevention of pregnancy loss in women with antiphospholipid antibodies (APLA). Anticoagulant therapy is also increasingly being employed for prevention of pregnancy complications in women with hereditary thrombophilia. Anticoagulant use during pregnancy is challenging because of the potential for fetal, as well as maternal, complications and because there is a paucity of high-quality clinical trials in this patient population upon which to make management decisions. This chapter will review the use of anticoagulants during pregnancy and in breast-feeding women and provide recommendations for the treatment and prevention of VTE, anticoagulant management in women with prosthetic mechanical valves, and prevention of pregnancy complications in women with thrombophilias.
- Open Access
Screening for Antiphospholipid Antibodies in Women With Pregnancy Complications: Response
- 1 January 2011
- Published by Elsevier
- p. 232-252
Anticoagulants